COMMUNIQUÉ RÉGLEMENTÉ
News
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Déclaration hebdomadaire d'opérations effectuées du 22 au 26 juillet 2024
-
COMMUNIQUÉ RÉGLEMENTÉ
Disclosure of transactions in own shares on July 22 to July 26, 2024
-
-
COMMUNIQUÉ DE PRESSE
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit
Applied DNA Sciences, Inc. will present Linea™ IVT platform at 4th Annual mRNA-based Therapeutics Summit to reduce dsRNA contamination in mRNA production, enabling faster and more efficient workflows -
COMMUNIQUÉ DE PRESSE
Knorr-Bremse Aktiengesellschaft: Knorr-Bremse publishes preliminary results for the second quarter of 2024 and raises guidance
Knorr-Bremse AG publishes preliminary results for Q2 2024, exceeding analysts' expectations, with a strong increase in operating EBIT and free cash flow. Full-year guidance raised due to 'BOOST 2026' strategy -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Knorr-Bremse Aktiengesellschaft: Knorr-Bremse Publishes Preliminary Financial Figures for the Second Quarter of 2024 and Raises Guidance for 2024
Knorr-Bremse AG raises 2024 guidance based on strong Q2/24 results. Key figures exceed expectations. Increased operating EBIT margin forecasted -
-
-
COMMUNIQUÉ DE PRESSE
New Research Supports PillSafe’s Methodology in Reducing the Risk of Medication Misuse and Overuse
Study reveals overprescribing medications leads to unused medication and opioid misuse. PillSafe's smart pill delivery system addresses prescription compliance and prevents medication abuse
